Groupe d'Etude en Oncologie du Quebec

Titre	A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
Protocole ID	CA102-003
ClinicalTrials.gov ID	NCT04943900
Type(s) de cancer	Tumeurs solides
Phase	Phase I
Type étude	Clinique
Médicament	BMS-986416 seul ou en association avec le nivolumab
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	Montréal
Investigateur(trice) principal(e)	Dre Rahima Jamal
Coordonnateur(trice)	Adeline Hamon 514-890-8000 poste 30737
Statut	Actif en recrutement
Critètes d'éligibilité	Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC) Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Disease amenable to serial biopsy
Critètes d'exclusion	Uncontrolled or significant cardiovascular disease Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted) Other protocol-defined inclusion/exclusion criteria apply

Groupe d'étude en oncologie du Québec